AbCellera (ABCL) Director Hayden Michael R Buys 46,387 Shares

What Happened
Hayden Michael R, a director of AbCellera Biologics Inc. (ABCL), made an open‑market purchase of 46,387 shares on August 12, 2026. The filing reports a weighted‑average purchase price of $10.37 per share for a total reported transaction value of approximately $481,033. This transaction is coded as a purchase (P).

Key Details

• Transaction date: 2026-08-12; Form 4 filed: 2026-08-14 (timely filing).
• Price: weighted‑average $10.37; reported price range across multiple trades: $10.25 to $10.45 (Footnote F1). The reporter can provide per‑trade breakdown on request.
• Shares acquired: 46,387; total value reported: ~$481,033.
• Transaction code: P = Purchase (open‑market or private purchase).
• Post‑transaction holdings: not specified in the provided filing.
• Footnote F2: These shares are held by Genworks 2 Consulting, Inc.; the reporting person’s spouse has sole voting and investment power over those shares. The reporting person disclaims beneficial ownership except for any indirect pecuniary interest.

Context
This was a direct purchase by a company director. Purchases by insiders are often of interest to retail investors because they indicate the insider is acquiring shares, but they do not by themselves predict future performance. The filing provides a weighted average price and a range; if you want the exact per‑trade prices, the filer offers to supply that breakdown on request.